Concerns about the COVID-19 shots have increased after a report that drug maker Moderna failed to inform the U.S. government ...

Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The ...

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

Hospitalizations and general "syndromic" cases were at 10+ statewide for the week. The number of reported COVID cases ...

Jared Holz, Mizuho Healthcare Sector strategist, joins 'Closing Bell Overtime' to talk Moderna and Novo Nordisk.

The biotech, renowned for its pioneering development of vaccines ... could be the booster shot the stock needs to generate a rebound. It's been more than four years since Moderna rose to ...

Moderna stock has been under pressure amid declining sales of its COVID-19 vaccine. The company projects ... in clinical trials that could be the booster shot the stock needs to generate a rebound.

Moderna has reported preliminary clinical ... "We believe that a bivalent booster vaccine, if authorised, would create a new tool as we continue to respond to emerging variants," added Bancel.

The biotech, renowned for its pioneering development of vaccines ... could be the booster shot the stock needs to generate a rebound. Let's discuss the pros and cons of buying Moderna stock.

researchers recommended that people who received it get a second booster dose with an mRNA vaccine such as Moderna and Pfizer. According to the published results, there were 129 coronavirus ...